Lirum Therapeutics Announces Positive Data on LX-101, a Novel Clinical-Stage Targeted Therapy Demonstrating Potent Preclinical Activity Against IGF-Related Cancers
Lirum Therapeutics, Inc. recently announced the acceptance for presentation of positive data on LX-101, a novel clinical-stage targeted therapy directed to the insulin-like growth factor 1 receptor (IGF-1R), at the 2024 European Society for Medical Oncology (ESMO) Sarcoma and Rare Cancers Congress held March 14-16 in Lugano, Switzerland.
Lirum’s data covers clinically-tested LX-101’s potent preclinical anti-tumor activity against cancers with well-established IGF-1R pathway involvement, including malignancies with known genetic alterations affecting the IGF-1R pathway and/or with high IGF-1R expression. The poster is available on the Lirum website (www.lirumtx.com) under the Investors and Media tab.
Given these promising results and the existing clinical data, Lirum is planning new clinical trials with LX-101 focused on oncologic indications, both pediatric and adult, that carry well-established ties to the IGF-1/IGF-1R pathway. Lirum is also developing LX-101 in certain autoimmune diseases, including thyroid dye disease, where IGF-1R has been clinically and commercially validated.
Lirum is an innovative clinical-stage biopharmaceutical company focused on the treatment of debilitating diseases through the acquisition, development and commercialization of novel drug candidates with compelling mechanisms of action, regulatory pathways and commercial opportunities. Lirum’s lead candidate, LX-101, is a novel clinical-stage targeted therapy directed to the insulin-like growth factor-1 receptor (IGF-1R) with a differentiated mechanism of action. Lirum is developing LX-101 in oncology and autoimmune indications, including thyroid eye disease (TED). For more information, visit www.lirumtx.com.
Total Page Views: 677
